Caprini Score in Venous Surgery: a Prospective Cohort Study (CAPSIVS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03041805 |
Recruitment Status :
Recruiting
First Posted : February 3, 2017
Last Update Posted : January 12, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Venous Thromboembolism Varicose Veins | Procedure: EVLT Procedure: RFA Procedure: USFS Procedure: HL/stripping Procedure: Miniphlebectomy Procedure: Sclerotherapy Device: GCS Drug: LMWH |
A prospective cohort study based on the platform of Ongoing Registry of Treatment of Chronic Venous Diseases (NCT03035747). The study will enrol adult patients undergoing any kind of varicose veins surgery with and without any prophylaxis. The patients should be examined for venous thromboembolic complications during 2-4 weeks after the procedure with mandatory duplex ultrasound.
The study will provide following information:
- the rate of asymptomatic DVT after varicose veins surgery
- the rate of symptomatic VTE after varicose veins surgery
- the rate of thermal-induced thrombosis (EHIT) after endovenous thermal ablation
- the ability of Caprini scores to predict VTE after varicose veins surgery
- identification of patients with high risk of VTE who will benefit from prophylaxis, especially with anticoagulation
Study Type : | Observational |
Estimated Enrollment : | 3000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Prospective Cohort Register Study for Validation of Caprini Score in Patients Undergoing Varicose Vein Surgery |
Actual Study Start Date : | January 1, 2017 |
Estimated Primary Completion Date : | January 1, 2025 |
Estimated Study Completion Date : | January 1, 2025 |

- Procedure: EVLT
Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
- Procedure: RFA
Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
- Procedure: USFS
Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
- Procedure: HL/stripping
High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
- Procedure: Miniphlebectomy
Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
- Procedure: Sclerotherapy
Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
- Device: GCS
Graduated compression stockings may be used after procedure by the decision of the doctor
- Drug: LMWH
Low-molecular-weight heparin may be used after procedure by the decision of the doctor
- any episode of VTE [ Time Frame: 0-4 weeks after procedure ]symptomatic or asymptomatic, confirmed by instrumental diagnostics
- symptomatic deep vein thrombosis [ Time Frame: 0-4 weeks after procedure ]symptomatic deep vein thrombosis confirmed by duplex ultrasound
- symptomatic pulmonary embolism [ Time Frame: 0-4 weeks after procedure ]symptomatic pulmonary embolism confirmed by perfusion isotope scanning or CT pulmonary angiography
- asymtomatic deep vein thrombosis [ Time Frame: 2-4 weeks after procedure ]asymptomatic DVT revealed by duplex ultrasound
- endovenous thermal-induced thrombosis [ Time Frame: 0-4 weeks after procedure ]EHIT revealed by duplex ultrasound
- major bleeding [ Time Frame: 0-4 weeks after procedure ]Fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in haemoglobin level of 20 g/L or more, or leading to transfusion of two or more units of whole blood or red cells.
- clinicaly relevant bleeding [ Time Frame: 0-4 weeks after procedure ]any non-major bleeding need for treatment or intervention
- death for any reason [ Time Frame: 0-4 weeks after procedure ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- age over 18 years
- any kind of varicose vein surgery
- follow up for 4 weeks after the procedure
- examination for VTE at 2-4 weeks after the procedure, including duplex ultrasound
Exclusion Criteria:
- lost for follow-up during 4 weeks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03041805
Contact: Kirill Lobastov, PhD | +7-985-211-63-31 | lobastov_kv@hotmail.com |
Russian Federation | |
Pirogov Russian National Research Medical University | Recruiting |
Moscow, Russian Federation, 117997 | |
Contact: Kirill Lobastov, PhD +7-985-211-63-31 lobastov_kv@hotmail.com |
Study Chair: | Kirill Lobastov, PhD | Pirogov Russian National Research Medical University |
Responsible Party: | Kirill Lobastov, Associated Professor, Pirogov Russian National Research Medical University |
ClinicalTrials.gov Identifier: | NCT03041805 |
Other Study ID Numbers: |
CAPSIVS |
First Posted: | February 3, 2017 Key Record Dates |
Last Update Posted: | January 12, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
venous thromboembolism deep vein thrombosis pulmonary embolism varicose veins surgery |
endovenous laser treatment radiofrequency ablation ultrasound-guided foam sclerotherapy register anticoagulation |
Thromboembolism Venous Thromboembolism Varicose Veins |
Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |